A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).

Dana M. Roque,Stefania Bellone,Eric R. Siegel,Natalia Buza,Elena Bonazzoli,Adele Guglielmi,Luca Zammataro,Nupur Nagarkatti,Samir Zaidi,Jung Soo Lee,Peter E. Schwartz,Elena Ratner,Ludmil B. Alexandrov,Akiko Iwasaki,Yong Kong,Eric Song,Weilai Dong,Julia A. Elvin,Jungmin Choi,Alessandro D. Santin

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).

2021

5523Background: Microsatellite instability (MSI-H) is a biomarker for response to immune-checkpoint inhibitors (ICIs); however, these neoplasms are heterogenous including Lynch (germline), Lynch-li...

Keywords:

Endometrial cancer
Cancer research
Microsatellite instability
Medicine
Biomarker (medicine)
Pembrolizumab
Germline

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations